Skip to content

Details

https://secure.meetupstatic.com/photos/event/a/3/f/4/600_461441972.jpeg

Modern medicine has cured us of many diseases and increased our lifespan. The biggest foe that still stumps scientists has been called “the emperor of all maladies” because there are too many genetic and environmental factors that contribute to cancer's different molecular mechanisms and characteristics. It is also difficult to target treatments specifically to cancer cells and not affect normal cells. Furthermore, there is great fear that cancer can unknowingly strike for anyone at anytime anywhere.

Despite spending $5 billion per year on cancer research, mankind is only beginning to scratch the surface of understanding and potentially curing the disease. Join us in hearing about the latest molecular strategies that promising startups are taking: gene therapy, blocking cancer signaling, single-cell sorting, and reverting cancer stem cells.

Come ask your questions and network with biotech professionals. Drinks and light snacks served.

Speakers:

https://secure.meetupstatic.com/photos/event/a/4/0/a/600_461441994.jpeg

Mubhij Ahmad, CEO of DNAlite (http://dnalite.com)

DNALite Therapeutics is developing gene therapy treatments for the gastrointestinal tract. The first lead candidate is for colon cancer, which is the second deadliest cancer in the U.S.

https://secure.meetupstatic.com/photos/event/a/4/4/c/600_461442060.jpeg

Aman Iqbal, CEO of Proteorex Therapeutics (http://proteorex.com/)

Proteorex is discovering small-molecule drugs to treat diseases with the greatest unmet medical need. Their platform can rapidly and cost-effectively unlock previously undruggable targets and has produced multiple partnered lead compounds.

https://secure.meetupstatic.com/photos/event/a/4/7/c/600_461442108.jpeg

John Butler, CEO of QuantumCyte (http://quantumcyte.com/)

QuantumCyte is enabling a deeper understanding of the immune system and cancer biology by enabling next-gen single cell analysis. Their technology has unprecedented ability to analyze large numbers of cells at industry leading resolution.

https://secure.meetupstatic.com/photos/event/a/4/a/c/600_461442156.jpeg

Attila Hajdu, CEO of Stelvio Oncology (https://www.stelvio-oncology.com)

Stelvio is focused on delivering precision medicine diagnostics and novel therapeutics for glioblastoma. The resistance of high-grade glioma to conventional cytotoxic drugs has prompted our development of a novel approach to therapy, including differentiating glioma stem cells to less tumorigenic cell fates.

Related topics

You may also like